Cholecystectomy reduces subsequent cholangiocarcinoma risk in choledocholithiasis patients undergoing endoscopic intervention

Table 3 Recurrent biliary event incidence and relationship with cholangiocarcinoma incidence among patients with choledocholithiasis underwent therapeutic endoscopic retrograde cholangiopancreatography, endoscopic retrograde cholangiopancreatography and cholecystectomy, or without intervention (excluding cholangiocarcinoma in the first 18 mo)

Variable	Number of RBE events	Number of RBE patients	RBE per person (SD)	Incidence proportion (person)	Person-years	Cholangiocarcinoma incidence rate/1000 person-years	RBEs incidence rate/1000 person-years	P value
ES/EPBD, n = 511	581	126	1.14 (2.28)	24.66%	1659.70	7.23	350.06	< 0.0011
ES/EPBD and CCY, n = 100	70	14	0.70 (1.36)	14.00%	393.11	2.54	178.07	< 0.0011
Choledocholithiasis without intervention, n = 1485	1213	286	0.82 (1.52)	19.26%	4364.45	2.52	277.93	Reference
Patients had cholangiocarcinoma after 18 mo, n = 24	43	10	1.79 (2.06)	41.67%	81.47	NA	527.79	< 0.001
Patients without cholangiocarcinoma, n = 1963	1812	414	0.92 (1.76)	21.09%	6320.31	NA	286.69	Reference

¹Z-score. ES: Endoscopic sphincterotomy; EPBD: Endoscopic papillary balloon dilatation; CCY: Cholecystectomy; RBE: Recurrent biliary event; NA: Not applicable.